Sanofi's next chapter in Pompe: $150M for Maze pact as the biotech gears up in CKD
With nearly $400 million to its name since Third Rock launched the biotech in 2019, Maze Therapeutics has lined up a deal that sees Sanofi snag its Pompe disease program after touting Phase I data in March and last December.
Sanofi will pay $150 million in upfront cash and future equity in the private biotech and another $600 million could come Maze’s way via biobucks for its oral candidate MZE001, back-up programs and IP around its GYS1 program, the companies said Monday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.